Publications & Présentations Scientifiques

PXL065 - Deuterium-Stabilized Thiazolidinediones

Phase 1b Study of PXL065 (Deuterium-Stabilized R-Pioglitazone), a Novel NASH Candidate, Predicts 15 mg Equivalent to 45 mg Actos®

Sebastien Bolze, et al. — November 2020, AASLD (American Association for the Study of Liver Diseases)

Phase 1 Study of PXL065 Confirms Dose-Proportionality & Stabilization of the Preferred Stereoisomer (R-Pioglitazone) for the Treatment of NASH

Bolze et al. — November 2019, AASLD (American Association for the Study of Liver Diseases), Boston, MA, USA

Safety, Tolerability & PK of PXL065*, the Stabilized R-Stereoisomer of Pioglitazone: A Mitochondrial Function Modulator for NASH without PPARγ Agonism & Related Side Effects

Vincent Jacques et al. — November 2018, AASLD (American Association for the Study of Liver Diseases), San Francisco, USA

DRX-065: A Novel Mitochondrial Modulator

Sheila DeWitt et al. — March 2018, NASH-TAG Oral presentation

PXL770 - AMP Kinase Activators

PXL770, a Novel Direct AMP-activated Protein Kinase Activator Produces Greater Efficacy when Combined with Other Key Therapeutic Mechanisms Targeting NASH

Pierre-Axel Monternier, et al. — November 2020, AASLD (American Association for the Study of Liver Diseases)

PXL770, a Novel Direct AMP-activated Protein Kinase Activator, Improves Hepatic Mitochondrial Function in a Rodent NASH Model

Pierre-Axel Monternier, et al. — November 2020, AASLD (American Association for the Study of Liver Diseases)

PXL770, a New Direct AMP Kinase Activator, Acting on the Adipose Tissue and the Liver, Demonstrates Promising Effects for Treatment of Non-Alcoholic Steatohepatitis

Pascale Gluais-Dagorn et al. — November 2018, AASLD (American Association for the Study of Liver Diseases), San Francisco, USA

PXL770, a direct AMPK activator, shows favorable cardiac safety profile

Sophie Hallakou-Bozec et al. — October 2018, International Meeting on AMPK, Toronto, Canada

PXL770, a direct AMPK activator for the treatment of NASH, shows a favorable PK, tolerability and safety profile in humans

Sandrine Perrimond-Dauchy et al. — October 2018, International Meeting on AMPK, Toronto, Canada

PXL770, a novel direct AMPK activator, improves metabolic disorders in a diet-induced mouse model of obesity and diabetes EASD,

Sébastian Bolze et al. — September 2016, EASD (European Association for the Study of Diabetes), Munich, Germany

PXL770, a Novel Direct AMPK Activator, Inhibits Hepatic de novo Lipogenesis for the Treatment of Metabolic Disorders EASD

Sophie Hallakou-Bozec et al. — September 2016, EASD (European Association for the Study of Diabetes), Munich, Germany

PXL770 Demonstrates Therapeutic Potential as a New Direct AMP Kinase Activator WCIRDC

Sophie Hallakou-Bozec et al. — November 2015, WCIRDC (World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease), Los Angeles, USA

Imeglimin - Type 2 Diabetes

The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cells

Vial, G., et al. Endocrinol Diabetes Metab — 2021

Mechanism of Action of Imeglimin: A Novel Therapeutic Agent for Type 2 Diabetes

Hallakou-Bozec, S., et al. Diabetes Obes Metab — 2021

Long-term treatment with imeglimin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes (TIMES 2) (Phase 3)

J. Dubourg et al. — September 2020, EASD (European Association for the Study of Diabetes)

Imeglimin Preserves Islet β-cell Mass in Type 2 Diabetic ZDF Rats

Hallakou-Bozec, S., et al. Endocrinol Diabetes Metab — 2020

Imeglimin monotherapy in Japanese patients with type 2 diabetes: results from a randomised, 24-week, double-blind, placebo-controlled, phase IIb trial

J. Dubourg — September 2017, EASD (European Association for the Study of Diabetes), Lisbon, Portugal

Short- and long-term imeglimin treatment reduces metabolic syndrome-related diabetic cardiomyopathy

Marianne Lachaux et al. — August 2017, EASD (European Association for the Study of Diabetes), Barcelona, Spain

Imeglimin Opposes Development of Metabolic Syndrome Related Diabetic Cardiomyopathy

Marianne Lachaux et al. — June 2017, ADA (American Diabetes Association), San Diego, USA

Imeglimin Preserves β-cell Function and Mass in Male Zucker Diabetic Fatty Rats World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease

Sophie Hallakou-Bozec et al. — December 2016, WCIRDC (World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease), Los Angeles, California, USA

Imeglimin Improves Vascular Dysfunction in Type 2 Diabetes Animal Models EASD

Fouqueray P et al. — September 2016, EASD (European Association for the Study of Diabetes), Munich, Germany

Imeglimin Improves Insulin Sensitivity in an Adult STZ Rat Model ADA

Sophie Hallakou-Bozec et al. — June 2016, ADA (American Diabetes Association), New Orleans, USA

Imeglimin Increases Insulin Secretion in Response to Glucose as a Unique Mechanism of Action Depending on NAD Synthesis ADA

Sophie Hallakou-Bozec et al. — June 2016, ADA (American Diabetes Association), New Orleans, USA

Imeglimin, a New Oral Anti-Hyperglycemic Agent Controls Fasting and Post-Prandial Glucose through an Improvement in both Insulin Secretion and Insulin Sensitivity WCIRDC

Fouqueray P et al. — November 2015, WCIRDC (World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease), Los Angeles, USA

Dose Ranging-Study to Determine the Optimum Dose for Imeglimin, a Novel Treatment for Type 2 Diabetes.

Fouqueray P et al. — June 2015, ADA (American Diabetes Association), Boston, USA

Imeglimin decreases hepatic glucose production through a unique mitochondrial mechanism of action.

Vial G et al. — June 2014, ADA (American Diabetes Association), San Francisco, USA

Imeglimin: A new antidiabetic agent that provides added benefit to DPP-4 inhibitor therapy.

Fouqueray P et al. — June 2013, ADA (American Diabetes Association), Chicago, USA

The effects of the antidiabetic Imeglimin in hyperglycemic mice with septic shock.

Wagner F et al. — March 2012, ISICEM (International Symposium on Intensive), Brussels, Belgium

Imeglimin - A New Oral Anti-Diabetic that Targets the Three Key Defects of Type 2 Diabetes

Fouqueray, P., et al. Journal of Diabetes & Metabolism — 2011

Imeglimin, a novel glimin oral anti-diabetic, exhibits good glycemic control in type 2 diabetic patients.

Pirags V et al. — September 2010, EASD (European Association for the Study of Diabetes), Stockholm, Sweden